The integration of psychedelic compounds into mainstream medicine faces a critical design question that could determine therapeutic success rates across conditions from treatment-resistant depression to PTSD. Rather than following traditional pharmaceutical models where standardized protocols dominate, leading medical voices now advocate for personalized treatment frameworks that prioritize individual patient needs and preferences. The New England Journal of Medicine editorial highlights how psilocybin, MDMA, and other psychedelic therapies require fundamentally different clinical approaches compared to conventional psychiatric medications. Unlike daily antidepressants with predictable dose-response curves, psychedelic sessions involve intense psychological experiences lasting hours, where therapeutic outcomes depend heavily on environmental factors, practitioner relationships, and patient psychological preparation. Current FDA trials for MDMA-assisted therapy and psilocybin treatments have shown promising efficacy signals, but implementation challenges remain significant. The patient-driven model suggests allowing individuals greater input into session frequency, therapeutic modalities, and integration practices rather than rigid clinical protocols. This approach acknowledges that psychedelic healing often involves deeply personal psychological processes that resist standardization. However, balancing patient autonomy with clinical safety presents regulatory complexities, particularly given these compounds' Schedule I status and potential for adverse psychological reactions. The editorial reflects growing recognition that psychedelic medicine may require entirely new clinical frameworks, moving beyond the traditional doctor-prescribes, patient-complies model toward collaborative therapeutic partnerships. This paradigm shift could influence how other personalized medicine approaches evolve, particularly in psychiatry where individual variation in treatment response remains substantial.